When Jeanne Szurek, 69, was diagnosed with stage IV epidermal growth factor receptor (EGFR)-positive lung cancer in 2024, she wondered if her two adult children were at a higher risk of developing the ...

A peptide nucleic acid (PNA)-based mutant mRNA detection system was developed by Nielsen et al., prompting many trials applying PNA probes to the molecular genetics field 1,2,3,4,5. In addition to the ...

Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines all ...

Lung cancer affects non-smokers, with 25% of patients having never smoked, highlighting the need for awareness of persistent symptoms and environmental risk factors. Genetic testing is essential for ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

A lung cancer diagnosis can feel frightening. And when a family member is diagnosed, you might wonder about your own risk, prompting you to ask if lung cancer is hereditary. Smoking tobacco accounts ...

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as ...

Non-small cell lung cancer (NSCLC) can develop even if you’ve never smoked, due to factors like genetics, environmental pollutants such as radon and asbestos, chronic lung disease, and secondhand ...

Almost five new cases of lung cancer are diagnosed every minute globally and one of them would be a non-smoker. Screening gap remains one of the critical challenges of lung cancer prevention as most ...